Description
ADCC-enhanced Gomiliximab is a non-fucosylated anti-CD23 therapeutic biobetter antibody.
Antibody Indication
Allergic asthma
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced CD23 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
CD23
Alternative Names
Lumiliximab; 357613-86-6; IDEC-152; P5E8; gomiliximab; FCER2; Fc fragment of IgE, low affinity II, receptor for (CD23); CD23A, Fc fragment of IgE, low affinity II, receptor for (CD23A), FCE2; low affinity immunoglobulin epsilon Fc receptor; CD23; CLEC4J; BLAST-2;
Gene ID
2208
UniProt ID
P06734
Cellular Localization
Plasma membrane, Extracellular region or secreted
Involvement in Disease
Diseases associated with FCER2 include Chronic Conjunctivitis and Extrinsic Allergic Alveolitis.
Related Pathways
Its related pathways are Signaling by GPCR and Hematopoietic cell lineage.
Function
Low-affinity receptor for immunoglobulin E (IgE) and CR2/CD21. Has essential roles in the regulation of IgE production and in the differentiation of B-cells (it is a B-cell-specific antigen).
Post-translational modifications
N- and O-glycosylated. The secreted form sCD23 is produced by ADAM10-mediated ectodomain shedding.
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG1, κ
Antibody Clone
Gomiliximab
Description
Recombinant monoclonal antibody to CD23. Gomiliximab is a monoclonal antibody acting as an immunosuppressive drug for the treatment of allergic asthma. It targets the low affinity IgE receptor (FcεRII or CD23). The drug is a antibody from Macaca irus and Homo sapiens.
Antibody Indication
Allergic asthma
